Burges Salmon’s Corporate Finance team has advised biotech company Nodus Oncology, a novel biotech company, on its strategic acquisition of certain oncology based IP assets from Basilea Pharmaceutica International AG, which will assist Nodus in developing oncology based molecules inhibiting novel DNA damage.
Nodus was founded by Cumulus Oncology and in partnership with the Lead Discovery Center (LDC). It is led by Chief Executive Officer Dr Ian Waddell PhD. With more than 30 years’ experience in leading successful R&D programmes as well as extensive and in-depth oncology expertise, including in the DDR field, Dr Waddell brings the expertise needed to develop and deliver Nodus’ pipeline successfully.
Other key members of the Nodus team include Luis Toledo, PhD, Scientific Founder and Advisor, Nicola Broughton PhD, MBA, Chief Business Officer, Manuelle Debunne PhD, Chief Operating Officer and Scott Doak, Finance Director.
Founded in 2008, LDC was established as a novel approach to capitalise on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. LDC will act as the drug discovery arm of Nodus and participate in the development of all assets in Nodus’ pipeline.
Founded in 2017, Cumulus sources novel oncology assets from academic institutes, commercial drug discovery groups and biopharmaceutical companies. Burges Salmon has previously advised Cumulus on a £1.7 million investment round and on a significant investment fundraise of c. £4.1 million.
The Burges Salmon team advising on the Nodus Oncology deal was led by Edinburgh-based partner Danny Lee, alongside senior associate Katie Carter and solicitor Victoria MacAulay, all from the firm’s Corporate Finance team.
Danny Lee comments: “The Burges Salmon life sciences team continues to go from strength to strength, and supporting an ambitious company like Nodus Oncology demonstrates our commitment to the fast-paced and buoyant sector.”